Finance

Lists
Q2 2027 earnings • released • Revenue beat +1.61%
See results
4536:TYO
Santen Pharmaceutical Co Ltd
¥1,894.00
+0.64%
(+12.00) 1D
Nov 6, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4536...
Open
¥1,950
High
¥1,992
Low
¥1,851
Mkt. cap
610.46B
Avg. vol.
1.32M
Volume
3.35M
Dividend
2.01%
Quarterly dividend
¥9
Ex-dividend date
Sep 29, 2026
P/E ratio
15.81
52-wk high
¥2,254
52-wk low
¥1,484
EPS
¥120
Shares outstanding
407.09M
No. of employees
4K
Open
¥1,950
High
¥1,992
Low
¥1,851
Mkt. cap
610.46B
Avg. vol.
1.32M
Volume
3.35M
Dividend
2.01%
Quarterly dividend
¥9
Ex-dividend date
Sep 29, 2026
P/E ratio
15.81
52-wk high
¥2,254
52-wk low
¥1,484
EPS
¥120
Shares outstanding
407.09M
No. of employees
4K
News stories
From web sources and news partners
Profile
Santen Pharmaceutical Co., Ltd., is a Japanese pharmaceutical company, specializing in ophthalmology. With its ophthalmic products Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide, with its products being sold in over 50 countries. The company was founded in 1890 by Kenkichi Taguchi, as Taguchi Santendo, and in 1925, Santendo Co., Ltd. was established. In 2014 Santen announced that it has entered into an agreement with Merck & Co. to purchase Merck's ophthalmology products. Wikipedia
About Santen Pharmaceutical Co Ltd
CEOAkira Kurokawa | Shigeo Taniuchi
Employees3.97K
Founded1890
HeadquartersOsaka, Kansai, Japan
SectorHealth Care
IndustryPharmaceutical industry
Websitesanten.com
Last report
Nov 5, 2026
Fiscal period
Q2 2027
- / -
Revenue / Est. (JPY)
74.33B / 73.15B
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
69.14B
72.88B
80.86B
68.96B
Cost of goods sold
29.06B
32.14B
29.07B
28.97B
Cost of revenue
29.06B
32.14B
29.07B
28.97B
Research and development expenses
6.16B
6.00B
7.81B
6.25B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
21.31B
22.27B
19.75B
23.38B
Operating expense
29.74B
30.45B
33.79B
31.87B
Total operating expenses
58.80B
62.58B
62.86B
60.84B
Operating income
10.34B
10.30B
18.01B
8.12B
Other non operating income
-
2.00M
117.00M
-2.00M
EBT including unusual items
10.18B
10.44B
19.37B
8.33B
EBT excluding unusual items
10.18B
10.44B
17.82B
8.33B
Income tax expense
2.19B
2.30B
3.80B
1.14B
Effective tax rate
21.53%
22.00%
19.64%
13.62%
Other operating expenses
-6.00M
-28.00M
-933.00M
-55.00M
Net income
8.06B
7.88B
15.55B
7.19B
Net profit margin
11.66%
10.81%
19.23%
10.43%
Earnings per share
-
-
-
-
Interest and investment income
257.00M
455.00M
195.00M
957.00M
Interest expense
-415.00M
-318.00M
-
-738.00M
Net interest expenses
-158.00M
137.00M
195.00M
219.00M
Depreciation and amortization charges
-2.18B
-
-6.65B
-
EBITDA
15.03B
14.92B
22.56B
12.84B
Gain or loss from assets sale
-
-
3.84B
-
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps